Therapeutic implications of immunohistochemical expression pattern of the cancer stem cell marker (nestin) in basal and squamous cell carcinomas

Abstract

Cancer stem cells (CSC) are populations of cells responsible for tumor initiation, progression and therapeutic resistance in many cancers. In the present study, we aimed to investigate the expression pattern and clinical significance of the stem cell marker nestin, in Squaous cell carcinoma (SCC) and basal cell carcinoma (BCC).

Recurrent cutaneous basal cell carcinoma after surgical excision: A retrospective clinicopathological study

“…The reported rates of BCC recurrence vary widely in the range of 0.5–38% in different studies [ 28 ] but one of our study limitations is the inability to calculate the recurrence rate in our institution. Some authors performed some useful mmunohistochemical staining for BCCs [ 31 ] but here we depend only on the ordinary stains with carful microscopic examination by expert histologists and anatomical pathologists.…”

The relationship among integrin alpha 7, CD133 and Nestin as well as their correlation with clinicopathological features and prognosis in astrocytoma patients

“…Furthermore, ITGA7 not only acts as a potential cancer stem cell (CSC) marker, but also regulates multiple other CSC marker expressions (including CD44, CD90, CD133, SOX2, OCT3/4 and NANOG), meanwhile, these CSC markers (such as CD133 and Nestin) correlate with shorter overall survival (OS) in astrocytoma patients [9,11,[15][16][17]. Given the fact that ITGA7 regulates CSC marker expressions in several cancers, besides CD133 and Nestin are well-characterised CSC markers in astrocytoma, we hypothesized that ITGA7 assessment might have a potentially clinical value in astrocytoma patients [18][19][20][21]. However, no relevant research has been conducted yet.…”

The Relationship Among Integrin Alpha 7, CD133 and Nestin as Well as Their Correlation With Clinicopathological Features and Prognosis in Astrocytoma Patients

“…Furthermore, ITGA7 not only acts as a potential cancer stem cell (CSC) marker, but also regulates multiple other CSC marker expressions (including CD44, CD90, CD133, SOX2, OCT3/4 and NANOG), meanwhile, these CSC markers (such as CD133 and Nestin) correlate with shorter overall survival (OS) in astrocytoma patients [9,11,[15][16][17]. Given the fact that ITGA7 regulates CSC marker expressions in several cancers, besides CD133 and Nestin are well-characterised CSC markers in astrocytoma, we hypothesized that ITGA7 assessment might have a potentially clinical value in astrocytoma patients [18][19][20][21]. However, no relevant research has been conducted yet.…”